Reishi - Mediated Enhancement of Human Tissue Progenitor Cell Adhesion and Differentiation

• US 20080247989A1
• Filed: 09/21/2007
• Published: 10/09/2008
• Est. Priority Date: 09/21/2006
• Status: Abandoned Application

• Current Assignee: Academia Sinica (Government of The Republic of China)
• Original Assignee: Academia Sinica (Government of The Republic of China)
• Inventors: Wong, Chi-Huey, Chen, Wan-Yu, Shih, Daniel Tzu-Bi
• Application Number:
  US11/859,738
• Publication Number:
  US 20080247989A1
• Time in Patent Office: Days
• US Class Current: 424/85.2
• CPC Class Codes: A61K 36/074 Ganoderma
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid

Abstract

The present disclosure provides medicinally active extracts and fractions, and methods for using the same to increase eukaryotic cell adhesion, to increase differentiation of eukaryotic cells to produce increased numbers of B cells dendritic cells and chodrocytes, and to maintain undifferentiated hematopoietic cells. These methods and useful for modulating immune response, modulating hematopoietic activity, and engineering certain types of eukaryotic tissues.

Claims

1. A method comprising:

administering a sufficient amount of purified reishi extract to a subject;

so that the mononuclear cell expression of cell surface markers is increased by at least 1%.

2. The method of claim 1, wherein the cell surface markers are VCAM and/or NCAM.

3. The method of claim 1, wherein the cell surface markers are selected from the group consisting of immature dendritic cell markers.

4. The method of claim 3, where the immature dendritic cell markers are selected from the group consisting of CD1a, CD14, CD40, CD80, and CD86.

5. The method of claim 1, wherein the cell surface markers are selected from the group consisting of mature dendritic cell markers.

6. The method of claim 5, wherein the mature dendritic cell markers are selected from the group consisting of CD83.

7. The method of claim 1, wherein the cell surface markers are selected from the group consisting of hematopoietic cell markers.

8. The method of claim 7, wherein the hematopoeitic cell markers are selected from the group consisting of CD34, CD38, CD133, and CXCR4.

9. The method of claim 1, wherein the cell surface markers are selected from the group consisting of B cell markers.

10. The method of claim 9, wherein the B cell markers are selected from the group consisting of CD19.

11. The method of any of claim 3, wherein purified reishi is co-administered to a subject with at least one cytokine selected from the group consisting of IL-4 and GM-CSF.

12. A method comprising:

administering a sufficient amount of purified reishi to a subject;

so that the MSC and/or PLA expression of cell surface markers is increased by at least 1%.

13. The method of claim 12, wherein the cell surface markers are selected from the group consisting of BMP-2, aggrecan, and IL-1.

14. The method of claim 12, wherein purified reishi is co-administered to a subject with at least one compound selected from the group consisting of insulin, TGF-B1, and/or ascorbate-2-phosphate.

15. A method comprising:

administering a sufficient amount of purified reishi to a subject;

so that the percentage of subject MSC and/or PSA cells that lose expression of the CD34+/CD38−

cell proteome is decreased by at least 1%.

16. A device comprising:

an amount of skeleton forming agent;

an amount of reishi extract; and

wherein the device may be implanted

17. The device of claim 16, further comprising an amount of mononuclear cells.

18. The device of claim 16, further comprising an amount of MSC and/or PLA